Fingerprint
Dive into the research topics of 'A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically